

14. Magnuson BA, Jonaitis TS, Card JW. A brief review of the occurrence, use, and safety of food-related nanomaterials. *J Food Sci.* 2011;76(6):R126–33. doi:10.1111/j.1750-3841.2011.02170.x.
15. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. *Science.* 2012;338(6109):903–10. doi:10.1126/science.1226338.
16. Song Y, Li X, Du X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. *Eur Respir J.* 2009;34(3):559–67. doi:10.1183/09031936.00178308.
17. Liao HY, Chung YT, Lai CH, Lin MH, Liou SH. Sneezing and allergic dermatitis were increased in engineered nanomaterial handling workers. *Ind Health.* 2014;52(3):199–215.
18. Wu WT, Liao HY, Chung YT, Li WF, Tsou TC, Li LA, et al. Effect of nanoparticles exposure on fractional exhaled nitric oxide (FENO) in workers exposed to nanomaterials. *Int J Mol Sci.* 2014;15(1):878–94. doi:10.3390/ijms15010878.
19. Gao G, Ze Y, Li B, Zhao X, Zhang T, Sheng L, et al. Ovarian dysfunction and gene-expressed characteristics of female mice caused by long-term exposure to titanium dioxide nanoparticles. *J Hazard Mater.* 2012;243:19–27. doi:10.1016/j.jhazmat.2012.08.049.
20. Tassinari R, Cubadda F, Moracci G, Aureli F, D'Amato M, Valeri M, et al. Oral, short-term exposure to titanium dioxide nanoparticles in Sprague–Dawley rat: focus on reproductive and endocrine systems and spleen. *Nanotoxicology.* 2014;8(6):654–62. doi:10.3109/17435390.2013.822114.
21. Takahashi S, Matsuoka O. Cross placental transfer of 198Au-colloid in near term rats. *J Radiat Res.* 1981;22(2):242–9.
22. Semmler-Behnke M, Fertsch S, Schmid G, Wenk A, Kreyling. Uptake of 1.4 nm versus 18 nm gold nanoparticles in secondary target organs is size dependent in control and pregnant rats after intratracheal or intravenous application. In: *EuroNanoForum 2007 – nanotechnology in industrial applications.* 2007. Düsseldorf, Germany.
23. Yang H, Sun C, Fan Z, Tian X, Yan L, Du L, et al. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. *Sci Rep.* 2012;2:847. doi:10.1038/srep00847.
24. Qi W, Bi J, Zhang X, Wang J, Wang J, Liu P, et al. Damaging effects of multi-walled carbon nanotubes on pregnant mice with different pregnancy times. *Sci Rep.* 2014;4:4352. doi:10.1038/srep04352.
25. Tsuchiya T, Oguri I, Yamakoshi YN, Miyata N. Novel harmful effects of [60]fullerene on mouse embryos in vitro and in vivo. *FEBS Lett.* 1996;393(1):139–45.
26. Sumner SC, Fennell TR, Snyder RW, Taylor GF, Lewin AH. Distribution of carbon-14 labeled C60 ([14C]C60) in the pregnant and in the lactating dam and the effect of C60 exposure on the biochemical profile of urine. *J Appl Toxicol JAT.* 2010;30(4):354–60. doi:10.1002/jat.1503.
27. Takeda K, Suzuki K, Ishihara A, Kubo-Irie M, Fujimoto R, Tabata M, et al. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. *J Health Sci.* 2009;55:95–102. doi:10.1248/jhs.55.95.
28. Yamashita K, Yoshioka Y, Higashisaka K, Mimura K, Morishita Y, Nozaki M, et al. Silica and titanium dioxide nanoparticles cause pregnancy complications in mice. *Nat Nanotechnol.* 2011;6(5):321–8. doi:10.1038/nnano.2011.41.
29. Tian F, Razansky D, Estrada GG, Semmler-Behnke M, Beyerle A, Kreyling W, et al. Surface modification and size dependence in particle translocation during early embryonic development. *Inhal Toxicol.* 2009;21 Suppl 1:92–6. doi:10.1080/08958370902942624.
30. Noori A, Parivar K, Modaresi M, Messripour M, Yousefi MH, Amiri GR, et al. Effect of magnetic iron oxide nanoparticles on pregnancy and testicular development of mice. *Afr J Biotechnol.* 2011;10(7):1221–7. doi:10.5897/AJB10.1544.
31. Melnik EA, Buzulukov YP, Demin VF, Demin VA, Gmoshinski IV, Tyshko NV, et al. Transfer of Silver Nanoparticles through the Placenta and Breast Milk during in vivo Experiments on Rats. *Acta Nat.* 2013;5(3):107–15.

32. Chu M, Wu Q, Yang H, Yuan R, Hou S, Yang Y, et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. *Small*. 2010;6(5):670–8. doi:10.1002/sml.200902049.
33. Sadauskas E, Wallin H, Stoltenberg M, Vogel U, Doering P, Larsen A, et al. Kupffer cells are central in the removal of nanoparticles from the organism. *Part Fibre Toxicol*. 2007;4:10. doi:10.1186/1743-8977-4-10.
34. Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vahakangas KH. Kinetics of gold nanoparticles in the human placenta. *Reprod Toxicol*. 2008;26(2):130–7. doi:10.1016/j.reprotox.2008.06.008.
35. Zalgevičienė V, Kulvietis V, Bulotienė D, Didziapetriene J, Rotomskis R. The effect of nanoparticles in rats during critical periods of pregnancy. *Medicina*. 2012;48(5):256–64.
36. Wick P, Malek A, Manser P, Meili D, Maeder-Althaus X, Diener L, et al. Barrier capacity of human placenta for nanosized materials. *Environ Health Perspect*. 2010;118(3):432–6. doi:10.1289/ehp.0901200.
37. Grafmüller S, Manser P, Krug HF, Wick P, von Mandach U. Determination of the transport rate of xenobiotics and nanomaterials across the placenta using the ex vivo human placental perfusion model. *J Vis Exp JoVE*. 2013(76). doi:10.3791/50401.
38. Philbrook NA, Walker VK, Afrooz AR, Saleh NB, Winn LM. Investigating the effects of functionalized carbon nanotubes on reproduction and development in *Drosophila melanogaster* and CD-1 mice. *Reprod Toxicol*. 2011;32(4):442–8. doi:10.1016/j.reprotox.2011.09.002.
39. Pietroiusti A, Massimiani M, Fenoglio I, Colonna M, Valentini F, Palleschi G, et al. Low doses of pristine and oxidized single-wall carbon nanotubes affect mammalian embryonic development. *ACS Nano*. 2011;5(6):4624–33. doi:10.1021/nn200372g.
40. Fujitani T, Ohyama K, Hirose A, Nishimura T, Nakae D, Ogata A. Teratogenicity of multi-wall carbon nanotube (MWCNT) in ICR mice. *J Toxicol Sci*. 2012;37(1):81–9.
41. Blum JL, Xiong JQ, Hoffman C, Zelikoff JT. Cadmium associated with inhaled cadmium oxide nanoparticles impacts fetal and neonatal development and growth. *Toxicol Sci*. 2012;126(2):478–86. doi:10.1093/toxsci/kfs008.
42. Li PW, Kuo TH, Chang JH, Yeh JM, Chan WH. Induction of cytotoxicity and apoptosis in mouse blastocysts by silver nanoparticles. *Toxicol Lett*. 2010;197(2):82–7. doi:10.1016/j.toxlet.2010.05.003.
43. Chan WH, Shiao NH. Cytotoxic effect of CdSe quantum dots on mouse embryonic development. *Acta Pharmacol Sin*. 2008;29(2):259–66. doi:10.1111/j.1745-7254.2008.00743.x.
44. Hsieh MS, Shiao NH, Chan WH. Cytotoxic effects of CdSe quantum dots on maturation of mouse oocytes, fertilization, and fetal development. *Int J Mol Sci*. 2009;10(5):2122–35. doi:10.3390/ijms10052122.
45. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. *Nat Med*. 2004;10(11):1222–6. doi:10.1038/nm1121.
46. Li Y, Wang HY, Cho CH. Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. *J Pharmacol Exp Ther*. 1999;290(2):789–96.
47. Hills FA, Abrahams VM, Gonzalez-Timon B, Francis J, Cloke B, Hinkson L, et al. Heparin prevents programmed cell death in human trophoblast. *Mol Hum Reprod*. 2006;12(4):237–43. doi:10.1093/molehr/gal026.
48. Hossain N, Schatz F, Paidas MJ. Heparin and maternal fetal interface: why should it work to prevent pregnancy complications? *Thromb Res*. 2009;124(6):653–5. doi:10.1016/j.thromres.2009.08.001.
49. Myatt L, Cui X. Oxidative stress in the placenta. *Histochem Cell Biol*. 2004;122(4):369–82. doi:10.1007/s00418-004-0677-x.
50. Shimizu M, Tainaka H, Oba T, Mizuo K, Umezawa M, Takeda K. Maternal exposure to nanoparticulate titanium dioxide during the prenatal period alters gene expression related to

- brain development in the mouse. *Part Fibre Toxicol.* 2009;6:20. doi:10.1186/1743-8977-6-20.
51. Umezawa M, Tainaka H, Kawashima N, Shimizu M, Takeda K. Effect of fetal exposure to titanium dioxide nanoparticle on brain development – brain region information. *J Toxicol Sci.* 2012;37(6):1247–52.
 52. Takahashi Y, Mizuo K, Shinkai Y, Oshio S, Takeda K. Prenatal exposure to titanium dioxide nanoparticles increases dopamine levels in the prefrontal cortex and neostriatum of mice. *J Toxicol Sci.* 2010;35(5):749–56.
 53. Hougaard KS, Jackson P, Jensen KA, Sloth JJ, Loschner K, Larsen EH, et al. Effects of prenatal exposure to surface-coated nanosized titanium dioxide (UV-Titan). A study in mice. *Part Fibre Toxicol.* 2010;7:16. doi:10.1186/1743-8977-7-16.
 54. Jackson P, Halappanavar S, Hougaard KS, Williams A, Madsen AM, Lamson JS, et al. Maternal inhalation of surface-coated nanosized titanium dioxide (UV-Titan) in C57BL/6 mice: effects in prenatally exposed offspring on hepatic DNA damage and gene expression. *Nanotoxicology.* 2013;7(1):85–96. doi:10.3109/17435390.2011.633715.
 55. Fedulov AV, Leme A, Yang Z, Dahl M, Lim R, Mariani TJ, et al. Pulmonary exposure to particles during pregnancy causes increased neonatal asthma susceptibility. *Am J Respir Cell Mol Biol.* 2008;38(1):57–67. doi:10.1165/rcmb.2007-0124OC.
 56. Yoshida S, Hiyoshi K, Oshio S, Takano H, Takeda K, Ichinose T. Effects of fetal exposure to carbon nanoparticles on reproductive function in male offspring. *Fertil Steril.* 2010;93(5):1695–9. doi:10.1016/j.fertnstert.2009.03.094.
 57. Kyjovska ZO, Boisen AM, Jackson P, Wallin H, Vogel U, Hougaard KS. Daily sperm production: application in studies of prenatal exposure to nanoparticles in mice. *Reprod Toxicol.* 2013;36:88–97. doi:10.1016/j.reprotox.2012.12.005.
 58. Jackson P, Vogel U, Wallin H, Hougaard KS. Prenatal exposure to carbon black (printex 90): effects on sexual development and neurofunction. *Basic Clin Pharmacol Toxicol.* 2011;109(6):434–7. doi:10.1111/j.1742-7843.2011.00745.x.
 59. Jackson P, Hougaard KS, Vogel U, Wu D, Casavant L, Williams A, et al. Exposure of pregnant mice to carbon black by intratracheal instillation: toxicogenomic effects in dams and offspring. *Mutat Res.* 2012;745(1–2):73–83. doi:10.1016/j.mrgentox.2011.09.018.
 60. Jackson P, Hougaard KS, Boisen AM, Jacobsen NR, Jensen KA, Moller P, et al. Pulmonary exposure to carbon black by inhalation or instillation in pregnant mice: effects on liver DNA strand breaks in dams and offspring. *Nanotoxicology.* 2012;6(5):486–500. doi:10.3109/17435390.2011.587902.
 61. Umezawa M, Kudo S, Yanagita S, Shinkai Y, Niki R, Oyabu T, et al. Maternal exposure to carbon black nanoparticle increases collagen type VIII expression in the kidney of offspring. *J Toxicol Sci.* 2011;36(4):461–8.
 62. Vitale R, Fawcett DW, Dym M. The normal development of the blood-testis barrier and the effects of clomiphene and estrogen treatment. *Anat Rec.* 1973;176(3):331–44.
 63. Johanson CE. Permeability and vascularity of the developing brain: cerebellum vs cerebral cortex. *Brain Res.* 1980;190(1):3–16.
 64. Chemes HE. Infancy is not a quiescent period of testicular development. *Int J Androl.* 2001;24(1):2–7.
 65. Watson RE, Desesso JM, Hurtt ME, Cappon GD. Postnatal growth and morphological development of the brain: a species comparison. *Birth Defects Res A Clin Mol Teratol.* 2006;77(5):471–84. doi:10.1002/bdrb.20090.
 66. Jonakait GM. The effects of maternal inflammation on neuronal development: possible mechanisms. *Int J Dev Neurosci.* 2007;25(7):415–25. doi:10.1016/j.ijdevneu.2007.08.017.
 67. Gao X, Yin S, Tang M, Chen J, Yang Z, Zhang W, et al. Effects of developmental exposure to TiO₂ nanoparticles on synaptic plasticity in hippocampal dentate gyrus area: an in vivo study in anesthetized rats. *Biol Trace Elem Res.* 2011;143(3):1616–28. doi:10.1007/s12011-011-8990-4.

68. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. *Biomaterials*. 2008;29(12):1912–19. doi:10.1016/j.biomaterials.2007.12.037.
69. Balasubramanian SK, Jittiwat J, Manikandan J, Ong CN, Yu LE, Ong WY. Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. *Biomaterials*. 2010;31(8):2034–42. doi:10.1016/j.biomaterials.2009.11.079.
70. Li WQ, Wang F, Liu ZM, Wang YC, Wang J, Sun F. Gold nanoparticles elevate plasma testosterone levels in male mice without affecting fertility. *Small*. 2013;9(9–10):1708–14. doi:10.1002/smll.201201079.
71. Bai Y, Zhang Y, Zhang J, Mu Q, Zhang W, Butch ER, et al. Repeated administrations of carbon nanotubes in male mice cause reversible testis damage without affecting fertility. *Nat Nanotechnol*. 2010;5(9):683–9. doi:10.1038/nnano.2010.153.
72. Gao G, Ze Y, Zhao X, Sang X, Zheng L, Ze X, et al. Titanium dioxide nanoparticle-induced testicular damage, spermatogenesis suppression, and gene expression alterations in male mice. *J Hazard Mater*. 2013;258–259:133–43. doi:10.1016/j.jhazmat.2013.04.046.
73. Zhao X, Sheng L, Wang L, Hong J, Yu X, Sang X, et al. Mechanisms of nanosized titanium dioxide-induced testicular oxidative stress and apoptosis in male mice. *Part Fibre Toxicol*. 2014;11(1):47. doi:10.1186/s12989-014-0047-3.
74. Morishita Y, Yoshioka Y, Satoh H, Nojiri N, Nagano K, Abe Y, et al. Distribution and histologic effects of intravenously administered amorphous nanosilica particles in the testes of mice. *Biochem Biophys Res Commun*. 2012;420(2):297–301. doi:10.1016/j.bbrc.2012.02.153.
75. Zhu MT, Feng WY, Wang Y, Wang B, Wang M, Ouyang H, et al. Particokinetics and extrapulmonary translocation of intratracheally instilled ferric oxide nanoparticles in rats and the potential health risk assessment. *Toxicol Sci*. 2009;107(2):342–51. doi:10.1093/toxsci/kfn245.
76. Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, et al. Subchronic oral toxicity of silver nanoparticles. *Part Fibre Toxicol*. 2010;7:20. doi:10.1186/1743-8977-7-20.
77. Park EJ, Bae E, Yi J, Kim Y, Choi K, Lee SH, et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. *Environ Toxicol Pharmacol*. 2010;30(2):162–8. doi:10.1016/j.etap.2010.05.004.
78. van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, et al. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. *ACS Nano*. 2012;6(8):7427–42. doi:10.1021/nn302649p.
79. Lee JH, Kim YS, Song KS, Ryu HR, Sung JH, Park JD, et al. Biopersistence of silver nanoparticles in tissues from Sprague–Dawley rats. *Part Fibre Toxicol*. 2013;10:36. doi:10.1186/1743-8977-10-36.
80. Yokel RA, Au TC, MacPhail R, Hardas SS, Butterfield DA, Sultana R, et al. Distribution, elimination, and biopersistence to 90 days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. *Toxicol Sci*. 2012;127(1):256–68. doi:10.1093/toxsci/kfs067.
81. Kim JS, Yoon TJ, Yu KN, Kim BG, Park SJ, Kim HW, et al. Toxicity and tissue distribution of magnetic nanoparticles in mice. *Toxicol Sci*. 2006;89(1):338–47. doi:10.1093/toxsci/kfj027.
82. Kwon JT, Hwang SK, Jin H, Kim DS, Minai-Tehrani A, Yoon HJ, et al. Body distribution of inhaled fluorescent magnetic nanoparticles in the mice. *J Occup Health*. 2008;50(1):1–6.
83. Wang Z, Chen Z, Zuo Q, Song F, Wu D, Cheng W, et al. Reproductive toxicity in adult male rats following intra-articular injection of cobalt-chromium nanoparticles. *J Orthop Sci*. 2013;18(6):1020–6. doi:10.1007/s00776-013-0458-2.
84. Araujo L, Sheppard M, Löbenberg R, Kreuter J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution

- after suspension in surfactant solutions and in oil vehicles. *Int J Pharm.* 1999;176(2):209–24. doi:10.1016/S0378-5173(98)00314-7.
85. Yoshida S, Hiyoshi K, Ichinose T, Takano H, Oshio S, Sugawara I, et al. Effect of nanoparticles on the male reproductive system of mice. *Int J Androl.* 2009;32(4):337–42. doi:10.1111/j.1365-2605.2007.00865.x.
 86. Sycheva LP, Zhurkov VS, Iurchenko VV, Daugel-Dauge NO, Kovalenko MA, Krivtsova EK, et al. Investigation of genotoxic and cytotoxic effects of micro- and nanosized titanium dioxide in six organs of mice in vivo. *Mutat Res.* 2011;726(1):8–14. doi:10.1016/j.mrgentox.2011.07.010.
 87. Hassankhani R, Esmaeillou M, Tehrani AA, Nasirzadeh K, Khadir F, Maadi H. In vivo toxicity of orally administrated silicon dioxide nanoparticles in healthy adult mice. *Environ Sci Pollut Res Int.* 2015;22(2):1127–32. doi:10.1007/s11356-014-3413-7.
 88. Gromadzka-Ostrowska J, Dziendzikowska K, Lankoff A, Dobrzynska M, Instanes C, Brunborg G, et al. Silver nanoparticles effects on epididymal sperm in rats. *Toxicol Lett.* 2012;214(3):251–8. doi:10.1016/j.toxlet.2012.08.028.
 89. Li C, Taneda S, Taya K, Watanabe G, Li X, Fujitani Y, et al. Effects of inhaled nanoparticle-rich diesel exhaust on regulation of testicular function in adult male rats. *Inhal Toxicol.* 2009;21(10):803–11. doi:10.1080/08958370802524381.
 90. Ramdhan DH, Ito Y, Yanagiba Y, Yamagishi N, Hayashi Y, Li C, et al. Nanoparticle-rich diesel exhaust may disrupt testosterone biosynthesis and metabolism via growth hormone. *Toxicol Lett.* 2009;191(2–3):103–8. doi:10.1016/j.toxlet.2009.08.013.
 91. Guo LL, Liu XH, Qin DX, Gao L, Zhang HM, Liu JY, et al. Effects of nanosized titanium dioxide on the reproductive system of male mice. *Zhonghua nan ke xue = Nat J Androl.* 2009;15(6):517–22.
 92. Wiwanitkit V, Sereemasapun A, Rojanathanes R. Effect of gold nanoparticles on spermatozoa: the first world report. *Fertil Steril.* 2009;91(1):e7–8. doi:10.1016/j.fertnstert.2007.08.021.
 93. Ben-David Makhiluf S, Qasem R, Rubinstein S, Gedanken A, Breitbart H. Loading magnetic nanoparticles into sperm cells does not affect their functionality. *Langmuir.* 2006;22(23):9480–2. doi:10.1021/la061988z.
 94. Braydich-Stolle LK, Lucas B, Schrand A, Murdock RC, Lee T, Schlager JJ, et al. Silver nanoparticles disrupt GDNF/Fyn kinase signaling in spermatogonial stem cells. *Toxicol Sci.* 2010;116(2):577–89. doi:10.1093/toxsci/kfq148.
 95. Terzuoli G, Iacoponi F, Moretti E, Renieri T, Baldi G, Collodel G. In vitro effect of silver engineered nanoparticles on human spermatozoa. *J Siena Acad Sci.* 2011;3(1):27–9. doi:10.4081/jsas.2011.27.
 96. Zakhidow ST, Marshak TL, Malolina EA, Kulibin AY, Zelenina IA, Pavluchenkova SM, et al. Gold nanoparticles disturb nuclear chromatin decondensation in mouse sperm in vitro. *Biochem (Moscow) Suppl Ser A Membr Cell Biol.* 2010;4(3):293–6. doi:10.1134/S1990747810030074.
 97. Carone BR, Fauquier L, Habib N, Shea JM, Hart CE, Li R, et al. Paternally induced transgenerational environmental reprogramming of metabolic gene expression in mammals. *Cell.* 2010;143(7):1084–96. doi:10.1016/j.cell.2010.12.008.
 98. Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ. Chronic high-fat diet in fathers programs beta-cell dysfunction in female rat offspring. *Nature.* 2010;467(7318):963–6. doi:10.1038/nature09491.
 99. Dias BG, Ressler KJ. Parental olfactory experience influences behavior and neural structure in subsequent generations. *Nat Neurosci.* 2014;17(1):89–96. doi:10.1038/nn.3594.
 100. Gapp K, Jawaid A, Sarkies P, Bohacek J, Pelczar P, Prados J, et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. *Nat Neurosci.* 2014;17(5):667–9. doi:10.1038/nn.3695.
 101. Bal R, Turk G, Tuzcu M, Yilmaz O, Ozercan I, Kuloglu T, et al. Protective effects of nanostructures of hydrated C(60) fullerene on reproductive function in streptozotocin-diabetic male rats. *Toxicology.* 2011;282(3):69–81. doi:10.1016/j.tox.2010.12.003.

102. Srdjenovic B, Milic-Torres V, Grujic N, Stankov K, Djordjevic A, Vasovic V. Antioxidant properties of fulleranol C₆₀(OH)₂₄ in rat kidneys, testes, and lungs treated with doxorubicin. *Toxicol Mech Methods*. 2010;20(6):298–305. doi:10.3109/15376516.2010.485622.
103. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. *Proc Natl Acad Sci U S A*. 2008;105(38):14265–70. doi:10.1073/pnas.0805135105.

Chapter 9

Biocompatibility of Nanomaterials

Yasuo Yoshioka, Kazuma Higashisaka, and Yasuo Tsutsumi

Abstract

Remarkable progress has been made in the field of nanotechnology in the past decade. Many new nanoparticles, which are defined as particles with at least one dimension between 1 and 100 nm, have been created, and new medical applications for these nanoparticles are now expected. To be able to create effective and safe nanomedicines, more information is needed about the effects and safety of nanoparticles in vivo because physical properties such as material composition, particle size, surface area, surface chemistry, surface charge, and agglomeration state all influence nanoparticle biocompatibility, particularly with regard to activation of the complement, coagulation, and immune systems. In this chapter, we introduce the most recent developments in our understanding of the biocompatibility of nanoparticles and discuss how our current understanding translates to the field of nanomedicine.

Key words Coagulation, Complement, Immune response, Nanomedicine, Protein corona, Safety, Surface property, Toxicity

1 Introduction

Recent progress in the field of nanotechnology means that it is now possible to produce a wide variety of nanoparticles, which are particles that have at least one dimension between 1 and 100 nm. Compared with larger particles of the same material, nanoparticles have a larger surface area per unit weight, which produces desirable properties such as enhanced electrical conductivity, tensile strength, and chemical reactivity. Nanoparticles are already being used in the electronics, food, cosmetics, and medical industries. In the medical industry, the application of nanotechnology (nanomedicine) is expected to provide novel diagnostic and imaging technologies, photothermal therapies, and vaccine and drug delivery systems for poorly soluble or unstable drugs. Unlike larger, micrometer-sized particles, nanoparticles are small enough to be absorbed through biological barriers and therefore can enter almost all of the body's compartments, including cells and intracellular organelles. Furthermore, the targeting of nanoparticles to specific pathological sites may reduce the incidence of side effects by increasing drug

exposure at target sites while decreasing systemic exposure. Biodegradable lipid nanoparticles and biopolymer-based nanoparticles are already being used as drug delivery systems; however, applications using non-biodegradable nanoparticles are still in development and are yet to be authorized for the use in humans.

Our current knowledge of the factors that affect the safety of nanoparticles is insufficient for the development of safe and efficacious nanomedicines. Since nanoparticles can penetrate cells and tissues that are remote from the portal of entry to the body, we must further examine the potential risks to human health posed by nanoparticles. If nanoparticles are to be used successfully as next-generation medicines, it will also be essential to address the concerns expressed in the literature regarding nanoparticle toxicity by collecting as much information as possible on the pharmacological and toxicological profiles of nanoparticles. The toxicity of nanoparticles is related not only to the effects of the nanomaterial itself but also to the concentration and length of time the nanoparticle spends in the body's tissues. Therefore, in addition to analyses of toxicity, systematic and thorough analyses of the absorption, distribution, metabolism, and excretion profiles of nanoparticles are needed to determine which nanoparticles pose a risk to human health.

Biocompatibility is the ability of a material to produce an appropriate host response in a specific situation. The body responds to nanoparticles, as it does to any foreign substance that enters it, by initiating biological responses that result in clearance of the nanoparticles. If these biological responses are unwanted, they can result in toxicity and bio-incompatibility. A high degree of biocompatibility is achieved when a material interacts with the body without inducing unacceptable toxic, immunogenic, thrombogenic, or carcinogenic responses. The levels of these responses are determined in part by how the nanoparticle interacts with various biological substances such as immune cells, proteins, and lipids (Fig. 1). Parameters such as structure, size distribution, surface area, surface chemistry, surface charge, and agglomeration state, as well as sample purity, also contribute to the biocompatibility of




Fig. 1 Nanoparticles interact with various biological substances

2 Particle Si




Fig. 2 Several parameters contribute to the biocompatibility of nanoparticles

nanoparticles (Fig. 2). Therefore, to understand the biocompatibility of a particular nanoparticle, we must first comprehensively understand the interrelationships among the physical properties of the nanoparticle and its interactions with biological substances.

2 Particle Size and Surface Charge

The biocompatibility of a nanoparticle is greatly influenced by its physicochemical properties [1, 2]. Therefore, to better understand the effects of nanoparticles *in vivo*, each type of nanoparticle must be evaluated individually. Particle size and surface charge are key parameters that affect the cellular uptake and biological interactions of nanoparticles. For example, Qiu et al. have shown that among gold nanorods with similar surface charges, shorter nanorods are internalized to a greater degree than longer nanorods, suggesting that the length of gold nanorods influences their cellular uptake [3]. In addition, we detected 70-nm silica nanoparticles (nSP70) in the maternal liver, placenta, and brain of pregnant mice and in the fetal liver, after intravenous injection, whereas we did not detect larger, micro-sized silica particles [2]. Furthermore, nSP70 induced miscarriage and fetal growth restriction in pregnant mice, whereas micro-sized silica particles did not. These results demonstrate the importance of evaluating the relationship between a nanoparticle's size and its reproductive toxicity.

Recently, ultra-small nanoparticles (diameter, <10 nm) have been investigated for their potential use as nanomedicines. Huang et al. compared the localization and penetration of gold nanoparticles (diameter, 2, 6, or 15 nm) *in vitro* and *in vivo* and showed that smaller gold nanoparticles internalized into cancer

cells more efficiently than larger gold nanoparticles in vitro [4]. Furthermore, more of the 2- or 6-nm nanoparticles than of the 15-nm nanoparticles accumulated in tumor tissue after intravenous injection in mice. The 2- or 6-nm nanoparticles were distributed throughout the cytoplasm and nucleus of cancer cells both in vitro and in vivo; however, the 15-nm nanoparticles were observed only in the cytoplasm. Together, these results suggest that before developing novel medical applications for ultra-small nanoparticles, we must first examine their safety profiles in vitro and in vivo.

Many groups have reported that certain types of single-walled (SW) or multi-walled (MW) carbon nanotubes (CNTs) are cytotoxic and genotoxic in vitro, prompting concern in the literature about the potential risks of CNTs to human health. Recent reports have indicated that certain CNTs induce mesothelioma-like lesions in mice in a manner similar to that observed in asbestos-induced mesothelioma. For example, Takagi et al. showed that intraperitoneally administered pristine MW-CNTs induced mesothelioma in a p53 (+/-) mouse carcinogenesis model, which was attributed to both biopersistence and geometric resemblance to asbestos of the MW-CNTs [5]. Poland et al. have also reported the asbestos-like pathogenic behavior of long, pristine MW-CNTs, which was associated with the needlelike fiber shape of the MW-CNTs, and established a structure-activity relationship based on the length of the MW-CNTs [6]. Furthermore, long, fibrous MW-CNTs were shown to produce inflammation and fibrosis in the peritoneal cavity at a level that is similar to, or greater than, that produced by long asbestos fibers; however, neither short asbestos fibers nor short, tangled MW-CNTs caused any significant inflammation [7], suggesting that length, diameter, and physicochemical properties are related only to the safety profile of pristine MW-CNTs.

Size-independent effects of nanoparticles have also been reported. Jiang et al. examined the effects of gold and silver nanoparticles coated with antibodies that bind to the ErbB family of protein kinases during signaling processes such as cell death [8]. Nanoparticles with diameters in the 2- to 100-nm range were all shown to affect basic cellular signaling processes, with those with diameters of 40 or 50 nm having the greatest effect, suggesting that when designing nanomedicines we must optimize the particle size depending on how the nanomedicine will be used.

Aggregation is a phenomenon associated with most nanoparticles; however, few studies have examined the influence of aggregation on cellular uptake and toxicity. One study by Albanese et al. has shown that aggregation influences the uptake patterns of different gold nanoparticles [9].

Being able to manipulate the surface chemistry of nanoparticles, such as by adding functional groups to reduce surface reactivity or enhance stability, will be indispensable in the future for the development of nanoparticles for the use as nanomedicines.